Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.62 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
| ▸ | IL1B | P01584 | 1/20 | 0.62 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PDE6D | O43924 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26320519 | 1.00 | CRBN (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL26324033 | 1.00 | CRBN (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL26320573 | 1.00 | CRBN (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL26320556 | 0.99 | CRBN (0.63) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL283111 | 0.97 | CRBN (0.58) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL28612725 | 0.97 | CRBN (0.61) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL328600 | 0.96 | CRBN (0.59) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL28617990 | 0.96 | CRBN (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL17049841 | 0.90 | CRBN (0.59) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL18900417 | 0.90 | CRBN (0.63) | CRBNDDB1TNFIL1BIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885TNF 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.